Coherent Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Coherent Quarterly Cash Flow Statements Table
Quarterly
|
Annual
Unit: USD | 2022-04-02 | 2022-01-01 | 2021-10-02 | 2021-07-03 | 2021-04-03 | 2021-01-02 | 2020-10-03 | 2020-07-04 | 2020-04-04 | 2019-12-28 | 2019-09-28 | 2019-06-29 | 2019-03-30 | 2018-12-29 | 2018-09-29 | 2018-06-30 | 2018-03-31 | 2017-12-30 | 2017-09-30 | 2017-07-01 | 2017-04-01 | 2016-12-31 | 2016-10-01 | 2016-07-02 | 2016-04-02 | 2016-01-02 | 2015-10-03 | 2015-07-04 | 2015-04-04 | 2014-12-27 | 2014-09-27 | 2014-06-28 | 2014-03-29 | 2013-12-28 | 2013-09-28 | 2013-06-29 | 2013-03-30 | 2012-12-29 | 2012-09-29 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-10-01 | 2011-07-02 | 2011-04-02 | 2011-01-01 | 2010-07-03 | 2010-04-03 | 2010-01-02 | 2009-07-04 | 2009-04-04 | 2008-12-27 | 2008-06-28 | 2008-03-29 | 2007-12-29 | 2006-12-30 | 2005-12-31 | 2005-01-01 | 2004-07-03 | 2004-04-03 | 2003-12-27 | 2003-09-30 | 2003-06-28 | 2003-03-29 | 2002-12-28 | 2001-12-29 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | 33,676,000 | 30,265,000 | 21,058,000 | 30,262,000 | -158,215,000 | 144,000 | 7,689,000 | -8,708,000 | -418,913,000 | 5,793,000 | 624,000 | -3,099,000 | 20,750,000 | 35,550,000 | 73,185,000 | 66,970,000 | 65,302,000 | 41,901,000 | 73,752,000 | 61,117,000 | 41,845,000 | 30,408,000 | 30,785,000 | 18,650,000 | 17,781,000 | 20,286,000 | 27,302,000 | 13,264,000 | 18,413,000 | 17,430,000 | 19,097,000 | 12,999,000 | 15,307,000 | 11,703,000 | 20,515,000 | 16,685,000 | 15,002,000 | 14,153,000 | 12,548,000 | 17,208,000 | 16,155,000 | 17,051,000 | 31,380,000 | 19,022,000 | 23,723,000 | 19,113,000 | 14,404,000 | 8,480,000 | 4,179,000 | -7,015,000 | -9,130,000 | -14,679,000 | 8,402,000 | 6,125,000 | 4,729,000 | 10,758 | 9,316,000 | 5,391,000 | -306,000 | 1,927,000 | -20,483,000 | |||||
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 11,763,000 | 11,026,000 | 11,424,000 | 11,224,000 | 10,984,000 | 10,606,000 | 10,448,000 | 10,325,000 | 12,776,000 | 13,156,000 | 13,463,000 | 13,772,000 | 13,774,000 | 13,916,000 | 14,607,000 | 13,336,000 | 12,844,000 | 12,555,000 | 12,113,000 | 11,618,000 | 10,963,000 | 8,995,000 | 6,495,000 | 6,527,000 | 6,498,000 | 6,385,000 | 6,362,000 | 6,017,000 | 6,226,000 | 6,210,000 | 6,602,000 | 6,482,000 | 6,825,000 | 6,699,000 | 6,970,000 | 6,599,000 | 6,679,000 | 6,108,000 | 6,064,000 | 5,673,000 | 5,678,000 | 5,828,000 | 5,686,000 | 5,136,000 | 4,950,000 | 4,767,000 | 5,032,000 | 5,923,000 | 5,752,000 | 4,652,000 | 4,987,000 | 4,729,000 | 5,436,000 | 6,260,000 | 5,981,000 | 6,220 | 6,485,000 | 7,310,000 | 7,295,000 | 8,447,000 | 6,859,000 | 7,871,000 | 7,174,000 | 7,020,000 | 6,937,000 | 5,480,000 |
amortization of intangible assets | 830,000 | 1,383,000 | 2,559,000 | 3,109,000 | 2,451,000 | 2,614,000 | 2,962,000 | 2,947,000 | 11,907,000 | 12,312,000 | 13,735,000 | 18,626,000 | 14,032,000 | 15,067,000 | 14,401,000 | 15,209,000 | 15,329,000 | 15,100,000 | 16,253,000 | 15,452,000 | 16,763,000 | 12,088,000 | 2,249,000 | 2,032,000 | 2,077,000 | 2,092,000 | 2,068,000 | 1,960,000 | 2,036,000 | 2,180,000 | 2,312,000 | 2,402,000 | 2,434,000 | 2,445,000 | 2,454,000 | 2,724,000 | 3,408,000 | 1,181,000 | 1,436,000 | 1,723,000 | 1,611,000 | 1,636,000 | 1,879,000 | 1,851,000 | 2,257,000 | 2,095,000 | 2,041,000 | 1,956,000 | 1,961,000 | 1,907,000 | 1,894,000 | 1,943,000 | 2,165,000 | 2,229,000 | 2,206,000 | 1,943 | 2,306,000 | |||||||||
deferred income taxes | 4,456,000 | -4,070,000 | -5,268,000 | -1,734,000 | -56,207,000 | 12,615,000 | -2,674,000 | 2,814,000 | -22,700,000 | -1,911,000 | -6,721,000 | -3,756,000 | -2,948,000 | -1,505,000 | -1,773,000 | 4,301,000 | 958,000 | 13,121,000 | -21,716,000 | 7,584,000 | -6,911,000 | 1,291,000 | -6,414,000 | 2,297,000 | -2,161,000 | -3,492,000 | -4,474,000 | -1,171,000 | -505,000 | 6,988,000 | -5,070,000 | -1,037,000 | -457,000 | -1,621,000 | -882,000 | 2,475,000 | -2,425,000 | -275,000 | -2,668,000 | -2,186,000 | 618,000 | -527,000 | 4,840,000 | 9,070,000 | 83,000 | 8,096,000 | 2,545,000 | 4,456,000 | 6,921,000 | 2,760,000 | 3,393,000 | -5,534,000 | 5,954,000 | 2,012,000 | -10,483,000 | |||||||||||
amortization of debt issuance cost | 676,000 | 748,000 | 868,000 | 870,000 | 884,000 | 857,000 | 870,000 | 807,000 | 818,000 | 826,000 | 837,000 | 1,248,000 | 1,274,000 | 1,288,000 | 1,314,000 | 1,030,000 | 3,406,000 | 3,815,000 | 4,232,000 | 1,263,000 | 1,107,000 | 600,000 | ||||||||||||||||||||||||||||||||||||||||||||
(gain) loss on sale of assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation | 9,043,000 | 31,907,000 | 9,980,000 | 10,148,000 | 9,092,000 | 12,185,000 | 13,711,000 | 14,386,000 | 8,898,000 | 7,792,000 | 9,931,000 | 9,655,000 | 9,004,000 | 7,876,000 | 8,669,000 | 8,583,000 | 8,410,000 | 7,076,000 | 7,194,000 | 6,892,000 | 6,683,000 | 5,503,000 | 5,336,000 | 5,689,000 | 5,387,000 | 3,745,000 | 4,495,000 | 4,565,000 | 4,782,000 | 4,390,000 | 4,690,000 | 4,667,000 | 4,672,000 | 4,868,000 | 4,615,000 | 4,640,000 | 4,642,000 | 4,994,000 | 4,005,000 | 4,127,000 | 4,161,000 | 4,022,000 | 3,442,000 | 3,437,000 | 3,162,000 | 2,922,000 | 2,191,000 | 2,018,000 | 1,874,000 | 1,488,000 | 2,425,000 | 1,753,000 | 1,605,000 | 3,051,000 | 2,260,000 | 3,491 | 3,047,000 | |||||||||
non-cash restructuring charges | -13,000 | -14,000 | 1,252,000 | 318,000 | 558,000 | 3,509,000 | 126,000 | 554,000 | 915,000 | 599,000 | 488,000 | 11,798,000 | 247,000 | 76,000 | 282,000 | 525,000 | 9,000 | 430,000 | 2,044,000 | 82,000 | -46,000 | 4,359,000 | ||||||||||||||||||||||||||||||||||||||||||||
amortization of right of use assets | 3,675,000 | 3,813,000 | 5,744,000 | 4,567,000 | 4,452,000 | 4,427,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other non-cash expense | 1,988,000 | 939,000 | -434,000 | 1,295,000 | -25,000 | 219,000 | -4,218,000 | -757,000 | 2,175,000 | 229,000 | 2,919,000 | -1,274,000 | -1,225,000 | 1,000 | 365,000 | 102,000 | -285,000 | 377,000 | 1,242,000 | 576,000 | 165,000 | 46,000 | 30,000 | 4,000 | 142,000 | 70 | ||||||||||||||||||||||||||||||||||||||||
changes in assets and liabilities, net of effect of acquisitions: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | -22,299,000 | 4,328,000 | 4,522,000 | -5,414,000 | -27,416,000 | -359,000 | -18,619,000 | 7,969,000 | 29,434,000 | 34,320,000 | -3,012,000 | 44,530,000 | 16,925,000 | 23,635,000 | -19,500,000 | -33,305,000 | 7,004,000 | -1,219,000 | -28,997,000 | -20,721,000 | -7,215,000 | 4,417,000 | -13,330,000 | 1,138,000 | -1,687,000 | -3,646,000 | 5,538,000 | -22,078,000 | 3,681,000 | 2,760,000 | -10,940,000 | 7,323,000 | -21,328,000 | 19,754,000 | 11,207,000 | -12,894,000 | -13,539,000 | 19,452,000 | -1,336,000 | -15,496,000 | 2,525,000 | 9,161,000 | 1,387,000 | 1,522,000 | 8,579,000 | 10,121,000 | 2,892,000 | 6,205,000 | 17,435 | 2,330,000 | 14,042,000 | |||||||||||||||
inventories | -30,212,000 | -6,626,000 | 978,000 | -2,082,000 | 11,527,000 | 18,570,000 | 28,628,000 | 19,162,000 | -18,459,000 | -867,000 | 16,086,000 | 4,368,000 | 6,852,000 | -9,501,000 | 6,744,000 | -25,189,000 | -43,550,000 | -16,128,000 | -15,486,000 | -895,000 | -1,651,000 | 6,613,000 | -12,081,000 | -22,564,000 | -17,350,000 | -3,713,000 | 4,043,000 | -4,103,000 | 1,399,000 | 4,715,000 | 3,372,000 | -3,120,000 | -4,845,000 | -2,297,000 | 4,336,000 | -1,159,000 | -1,030,000 | 2,113,000 | 1,954,000 | -6,760,000 | -7,632,000 | 2,671,000 | -7,810,000 | 1,114,000 | 1,207,000 | 7,416,000 | 1,217,000 | 667,000 | 1,531 | 3,953,000 | ||||||||||||||||
prepaid expenses and other assets | -2,419,000 | -10,655,000 | 1,915,000 | -1,953,000 | -6,062,000 | -3,577,000 | -2,005,000 | 7,662,000 | -4,870,000 | -3,418,000 | 5,747,000 | -1,665,000 | 8,793,000 | 1,199,000 | 1,017,000 | -2,519,000 | 1,171,000 | -6,364,000 | -465,000 | -268,000 | -75,000 | -3,559,000 | -46,000 | 48,000 | -1,306,000 | -3,551,000 | 19,145,000 | -7,272,000 | -5,271,000 | -8,650,000 | 23,533,000 | -3,759,000 | 1,117,000 | -9,256,000 | 20,064,000 | 282,000 | -5,937,000 | -4,281,000 | 15,887,000 | -11,102,000 | -2,758,000 | -7,321,000 | 15,278,000 | 1,883,000 | 1,947,000 | |||||||||||||||||||||
other long-term assets | 11,780,000 | -2,723,000 | -2,547,000 | -3,022,000 | 9,575,000 | -2,071,000 | -4,124,000 | -740,000 | 5,602,000 | -3,471,000 | -2,210,000 | -639,000 | -32,000 | 2,332,000 | -2,323,000 | -1,616,000 | -388,000 | -3,365,000 | 557,000 | -1,027,000 | -1,209,000 | -1,083,000 | ||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 8,221,000 | -4,079,000 | -1,947,000 | 13,590,000 | 31,768,000 | -912,000 | -6,529,000 | 4,827,000 | 9,100,000 | 789,000 | -9,942,000 | -4,416,000 | -5,538,000 | 4,736,000 | -13,220,000 | -10,103,000 | 8,911,000 | 4,676,000 | 1,741,000 | -2,137,000 | 7,233,000 | 1,439,000 | -89,000 | 2,308,000 | 11,768,000 | -4,252,000 | 359,000 | 84,000 | 5,915,000 | -5,358,000 | 1,560,000 | -1,785,000 | 3,588,000 | -5,658,000 | -4,371,000 | 490,000 | 10,442,000 | -445,000 | -9,343,000 | 214,000 | 3,401,000 | -4,715,000 | -4,991,000 | -242,000 | 2,385,000 | 2,687,000 | 3,844,000 | 3,331,000 | 1,752,000 | -2,994,000 | 2,750,000 | 1,969,000 | ||||||||||||||
income taxes payable/receivable | 6,315,000 | -1,805,000 | 10,750,000 | 2,180,000 | 6,329,000 | 13,306,000 | 8,618,000 | -7,519,000 | -23,676,000 | -2,447,000 | -4,516,000 | -86,221,000 | -7,350,000 | -21,842,000 | -9,246,000 | -11,095,000 | -8,936,000 | 29,751,000 | 38,501,000 | 15,465,000 | 14,282,000 | -1,428,000 | 10,143,000 | -8,738,000 | 1,404,000 | 4,575,000 | 5,041,000 | -1,929,000 | -2,594,000 | -7,277,000 | 2,435,000 | -9,334,000 | -113,000 | -4,361,000 | 3,226,000 | -23,703,000 | 313,000 | -410,000 | 9,349,000 | 3,616,000 | -11,677,000 | -8,210,000 | -6,748,000 | 4,714,000 | 7,127,000 | 534,000 | 1,230,000 | |||||||||||||||||||
operating lease liabilities | -3,699,000 | -3,935,000 | -6,213,000 | -3,973,000 | -4,760,000 | -4,090,000 | -3,622,000 | -3,953,000 | -4,512,000 | -3,877,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other current liabilities | 8,640,000 | -36,447,000 | 8,018,000 | 7,771,000 | 31,889,000 | 6,766,000 | 4,209,000 | -5,289,000 | 7,951,000 | -7,856,000 | 3,582,000 | 3,934,000 | 14,000 | -20,685,000 | 26,814,000 | -28,059,000 | -2,239,000 | -39,336,000 | 7,609,000 | -7,197,000 | 29,135,000 | 17,911,000 | 26,142,000 | 698,000 | 8,949,000 | -5,128,000 | -13,554,000 | -2,717,000 | 14,749,000 | 7,145,000 | -20,524,000 | 5,614,000 | 9,080,000 | 5,250,000 | -20,087,000 | -91,000 | 4,937,000 | 4,056,000 | -17,597,000 | 10,758,000 | 4,589,000 | -3,110,000 | -12,394,000 | 248,000 | 19,608,000 | 1,250,000 | 17,328,000 | 12,444,000 | 7,409,000 | 9,739,000 | 2,249,000 | 2,536,000 | ||||||||||||||
other long-term liabilities | -14,341,000 | -1,974,000 | 1,638,000 | 4,248,000 | -10,074,000 | 122,000 | 5,352,000 | 5,759,000 | -5,736,000 | 3,968,000 | 13,957,000 | 2,180,000 | 440,000 | -832,000 | 36,000 | 2,024,000 | -125,000 | 2,588,000 | -2,415,000 | 3,678,000 | 721,000 | 1,330,000 | 1,887,000 | 3,144,000 | -2,922,000 | 1,843,000 | -1,376,000 | 1,412,000 | -732,000 | 816,000 | 1,178,000 | 1,028,000 | -600,000 | 3,301,000 | 277,000 | 1,577,000 | -773,000 | 821,000 | 1,526,000 | -728,000 | -767,000 | 676,000 | -1,618,000 | 1,752,000 | -22,000 | 2,431,000 | 1,196,000 | 1,356,000 | 2,307 | |||||||||||||||||
net cash from operating activities | 26,728,000 | 12,081,000 | 69,853,000 | 71,404,000 | -143,250,000 | 74,931,000 | 46,843,000 | 54,292,000 | 45,731,000 | 60,041,000 | 46,037,000 | 9,041,000 | 75,012,000 | 51,311,000 | 103,118,000 | 194,000 | 67,819,000 | 64,980,000 | 98,834,000 | 90,923,000 | 111,718,000 | 82,641,000 | 50,678,000 | 9,067,000 | 31,292,000 | 14,262,000 | 55,623,000 | -11,579,000 | 49,363,000 | 31,051,000 | 26,482,000 | 20,479,000 | 15,741,000 | 28,677,000 | 48,763,000 | -3,665,000 | 23,101,000 | 47,323,000 | 21,060,000 | 10,965,000 | 16,611,000 | 16,135,000 | 32,442,000 | 18,390,000 | 5,875,000 | 29,969,000 | 22,160,000 | 28,579,000 | 17,600,000 | 11,021,000 | 14,946,000 | 15,564,000 | 13,077,000 | 28,734 | 20,522,000 | 29,640,000 | 25,358,000 | 203,000 | ||||||||
capex | -18,118,000 | -16,884,000 | -22,067,000 | -23,451,000 | -21,972,000 | -15,073,000 | -16,483,000 | -13,037,000 | -23,903,000 | -11,496,000 | -22,772,000 | -18,986,000 | -18,388,000 | -23,137,000 | -24,767,000 | -21,039,000 | -21,268,000 | -23,683,000 | -18,422,000 | -15,809,000 | -14,153,000 | -15,390,000 | -21,017,000 | -12,054,000 | -11,491,000 | -4,765,000 | -5,976,000 | -3,977,000 | -7,072,000 | -5,138,000 | -5,528,000 | -3,867,000 | -7,203,000 | -6,792,000 | -6,622,000 | -4,874,000 | -6,591,000 | -3,901,000 | -5,438,000 | -11,038,000 | -11,436,000 | -8,139,000 | -9,669,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||||
free cash flows | 8,610,000 | -4,803,000 | 47,786,000 | 47,953,000 | -165,222,000 | 59,858,000 | 30,360,000 | 41,255,000 | 21,828,000 | 48,545,000 | 23,265,000 | -9,945,000 | 56,624,000 | 28,174,000 | 78,351,000 | -20,845,000 | 46,551,000 | 41,297,000 | 80,412,000 | 75,114,000 | 97,565,000 | 67,251,000 | 29,661,000 | -2,987,000 | 19,801,000 | 9,497,000 | 49,647,000 | -15,556,000 | 42,291,000 | 25,913,000 | 20,954,000 | 16,612,000 | 8,538,000 | 21,885,000 | 42,141,000 | -8,539,000 | 16,510,000 | 43,422,000 | 15,622,000 | -73,000 | 5,175,000 | 7,996,000 | 22,773,000 | 18,390,000 | 5,875,000 | 29,969,000 | 22,160,000 | 28,579,000 | 17,600,000 | 11,021,000 | 14,946,000 | 15,564,000 | 13,077,000 | 28,734 | 20,522,000 | 29,640,000 | 25,358,000 | 203,000 | ||||||||
cash flows from investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment | -18,118,000 | -16,884,000 | -22,067,000 | -23,451,000 | -21,972,000 | -15,073,000 | -16,483,000 | -13,037,000 | -23,903,000 | -11,496,000 | -22,772,000 | -18,986,000 | -18,388,000 | -23,137,000 | -24,767,000 | -21,039,000 | -21,268,000 | -23,683,000 | -18,422,000 | -15,809,000 | -14,153,000 | -15,390,000 | -21,017,000 | -12,054,000 | -11,491,000 | -4,765,000 | -5,976,000 | -3,977,000 | -7,072,000 | -5,138,000 | -5,528,000 | -3,867,000 | -7,203,000 | -6,792,000 | -6,622,000 | -4,874,000 | -6,591,000 | -3,901,000 | -5,438,000 | -11,038,000 | -11,436,000 | -8,139,000 | -9,669,000 | |||||||||||||||||||||||
proceeds from dispositions of property and equipment | 3,120,000 | 70,000 | 439,000 | 819,000 | 256,000 | 1,695,000 | 21,258,000 | -208,000 | 181,000 | 695,000 | 66,000 | 897,000 | 1,667,000 | 2,648,000 | 64,000 | 26,000 | 951,000 | 858,000 | 21,000 | 123,000 | 133,000 | 242,000 | 130,000 | 50,000 | -685,000 | 874,000 | 406,000 | 568,000 | 168,000 | -83,000 | 318,000 | 182,000 | 1,351,000 | 37,000 | 26,000 | 17,000 | 305,000 | 509,000 | -234,000 | 478,000 | 254,000 | 523,000 | 826,000 | 2,199,000 | 29,000 | 9,824,000 | 143 | 20,000 | 10,846,000 | 983,000 | 77,000 | 826,000 | ||||||||||||||
proceeds from sales and maturities of available-for-sale securities | 15,030,000 | 60,000 | 41,928,000 | 115,000 | 5,000 | 120,000 | 1,995,000 | 9,464,000 | -28,000 | 121,000 | -1,000 | 58,590,000 | 18,486,000 | 9,711,000 | 105,000 | 5,000 | 0 | 25,108,000 | 188,092,000 | 65,496,000 | 28,216,000 | 51,254,000 | 76,015,000 | 94,608,000 | 98,066,000 | 77,370,000 | 46,145,000 | 60,939,000 | 34,741,000 | 51,605,000 | 38,709,000 | 43,247,000 | 34,879,000 | 128,526,000 | 25,924,000 | 43,906,000 | 40,682,000 | 30,188,000 | 73,028,000 | 74,233,000 | 28,803,000 | 19,506,000 | 43,863,000 | 30,780,000 | 22,506,000 | 24,930,000 | 21,322,000 | 4,112,000 | -411,785,000 | 431,120,000 | 130,266,000 | 176,506 | 80,778,000 | 80,875,000 | 103,678,000 | 51,182,000 | 95,440,000 | |||||||||
net cash from investing activities | -14,998,000 | -16,814,000 | -6,598,000 | -51,382,000 | -1,495,000 | -13,378,000 | 11,362,000 | -55,027,000 | -23,838,000 | -10,681,000 | -20,711,000 | -8,744,000 | -20,518,000 | -50,320,000 | -23,220,000 | 24,964,000 | -65,640,000 | -3,840,000 | -49,921,000 | -15,279,000 | -14,295,000 | -730,793,000 | 167,208,000 | -42,529,000 | -17,623,000 | -3,612,000 | 22,294,000 | -5,623,000 | -42,524,000 | 29,020,000 | -78,443,000 | -14,291,000 | -14,820,000 | -2,229,000 | -24,487,000 | -15,009,000 | -24,875,000 | -6,294,000 | -38,565,000 | -9,175,000 | -104,686,000 | 9,482,000 | 5,564,000 | 5,904,000 | ||||||||||||||||||||||
cash flows from financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of short-term borrowings | -444,000 | -10,452,000 | -463,000 | -472,000 | -471,000 | -468,000 | -464,000 | -442,000 | -1,330,000 | -12,238,000 | -43,074,000 | -20,485,000 | -21,759,000 | -26,476,000 | -25,033,000 | -28,763,000 | -36,333,000 | -622,000 | -1,579,000 | -540,000 | -4,780,000 | -23,920,000 | 0 | -5,000,000 | -17,632,000 | -12,160,000 | -14,375,000 | -4,869,000 | -7,943,000 | -11,542,000 | -16,408,000 | -8,323,000 | -15,614,000 | -21,154,000 | -11,177,000 | -6,341,000 | 0 | 0 | ||||||||||||||||||||||||||||
repayments of long-term borrowings | -1,863,000 | -1,933,000 | -2,038,000 | -2,304,000 | -2,117,000 | -2,104,000 | -2,055,000 | -1,981,000 | -1,928,000 | -1,956,000 | -1,851,000 | -1,884,000 | -1,895,000 | -1,907,000 | -2,307,000 | -2,373,000 | -76,550,000 | -90,363,000 | -90,754,000 | -52,477,000 | -34,178,000 | -2,171,000 | ||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock under employee stock purchase plans | 0 | 6,566,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net settlement of restricted common stock | -1,429,000 | -37,935,000 | -281,000 | -830,000 | -348,000 | -8,903,000 | -30,000 | -220,000 | -124,000 | -13,175,000 | -12,000 | -26,000 | -298,000 | -14,843,000 | -28,000 | -42,000 | -604,000 | -35,646,000 | -27,000 | -15,000 | -420,000 | -15,255,000 | -29,000 | -70,000 | -27,000 | -5,317,000 | -7,000 | -60,000 | -35,000 | -5,200,000 | -18,000 | -104,000 | -31,000 | -7,658,000 | -7,000 | -117,000 | 0 | -4,046,000 | -23,000 | -83,000 | -18,000 | -4,413,000 | -27,000 | |||||||||||||||||||||||
net cash from financing activities | -3,736,000 | -43,754,000 | 31,866,000 | -2,936,000 | -5,579,000 | -2,548,000 | 3,897,000 | -1,757,000 | -9,478,000 | -32,397,000 | -23,662,000 | -29,557,000 | 5,101,000 | -3,091,000 | -97,360,000 | -79,169,000 | -119,378,000 | -89,471,000 | -48,590,000 | -37,252,000 | 681,301,000 | -2,981,000 | 18,980,000 | -1,999,000 | 3,204,000 | -49,973,000 | 3,495,000 | -7,482,000 | -19,061,000 | 197,000 | -850,000 | 822,000 | 3,280,000 | 7,590,000 | -23,378,000 | 273,000 | -482,000 | 4,043,000 | -18,833,000 | -55,698,000 | 16,918,000 | -10,828,000 | 10,496,000 | 2,408,000 | 754,000 | 489,000 | 3,079,000 | 1,986 | 1,017,000 | 4,978,000 | 1,521,000 | 5,246,000 | ||||||||||||||
effect of exchange rate changes on cash, cash equivalents and restricted cash | -7,788,000 | -3,765,000 | -8,196,000 | -735,000 | -6,904,000 | 12,182,000 | 5,649,000 | 6,756,000 | -8,418,000 | 4,035,000 | -4,037,000 | 2,661,000 | -2,802,000 | -1,799,000 | 960,000 | -5,083,000 | 761,000 | 943,000 | 11,754,000 | 12,787,000 | 11,887,000 | -13,504,000 | ||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of period | 0 | 462,521,000 | 0 | 0 | 445,520,000 | 0 | 0 | 318,661,000 | 0 | 0 | 324,045,000 | 0 | 0 | 457,087,000 | 0 | 0 | 354,347,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of period | 206,000 | 410,269,000 | 51,153,000 | -154,585,000 | 513,676,000 | 9,918,000 | 11,718,000 | 362,578,000 | -20,704,000 | 22,135,000 | 328,338,000 | -77,285,000 | -76,229,000 | 399,792,000 | 39,841,000 | 72,058,000 | 373,992,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
non-cash investing and financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unpaid property and equipment purchases | -1,723,000 | 5,136,000 | -1,569,000 | 1,083,000 | -2,291,000 | 6,914,000 | -2,930,000 | 46,000 | -1,990,000 | 7,770,000 | -579,000 | -366,000 | -731,000 | 6,082,000 | 823,000 | 1,991,000 | -491,000 | 3,853,000 | 1,247,000 | -772,000 | -1,362,000 | 4,084,000 | 954,000 | -1,262,000 | 2,301,000 | 1,499,000 | 484,000 | 113,000 | ||||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | -52,252,000 | 52,277,000 | 51,153,000 | -154,585,000 | 68,156,000 | 61,306,000 | 9,918,000 | 11,718,000 | 43,917,000 | -11,108,000 | -20,704,000 | 22,135,000 | 4,293,000 | 77,767,000 | -77,285,000 | -76,229,000 | -57,295,000 | -28,804,000 | 39,841,000 | 72,058,000 | 19,645,000 | |||||||||||||||||||||||||||||||||||||||||||||
impairment of goodwill | 0 | 0 | 0 | 0 | 19,286,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of long-lived assets | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of investment | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash loss on or laser dissolution | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash pension impact | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of available-for-sale securities | -35,341,000 | -41,897,000 | 0 | -119,000 | -6,433,000 | -5,000,000 | -119,000 | -21,485,000 | -17,944,000 | -14,894,000 | 0 | -96,213,000 | -34,478,000 | -50,151,000 | -37,760,000 | -97,128,000 | -133,924,000 | -43,780,000 | -119,228,000 | -71,280,000 | -42,676,000 | -47,224,000 | -57,925,000 | -53,419,000 | -53,257,000 | -63,630,000 | -55,644,000 | -42,043,000 | -133,906,000 | -12,593,000 | -58,273,000 | |||||||||||||||||||||||||||||||||||
acquisition of businesses, net of cash acquired | 0 | 0 | 0 | 0 | -18,881,000 | 0 | 0 | 0 | 0 | 0 | -740,481,000 | 0 | 0 | 0 | -67,289,000 | 481,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
investment at cost | 0 | 0 | 0 | -3,423,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term borrowings | 0 | 0 | 551,000 | 12,144,000 | 12,540,000 | 18,630,000 | 20,300,000 | 68,124,000 | 24,277,000 | 28,143,000 | 34,318,000 | 2,354,000 | 1,261,000 | 672,000 | 3,010,000 | 3,920,000 | 0 | 20,000,000 | 17,632,000 | 17,160,000 | 14,375,000 | 4,869,000 | 7,943,000 | 11,542,000 | 15,596,000 | 9,159,000 | 15,614,000 | 21,154,000 | 11,177,000 | 6,341,000 | 0 | 0 | 4,476,000 | 4,786,000 | 793,000 | 687,000 | 579,000 | 285,000 | 4,000 | 1,000 | 0 | 34,000 | 676,000 | 3,963,000 | ||||||||||||||||||||||
long-term borrowings | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock under employee stock option and purchase plans | 0 | 6,587,000 | 0 | 5,896,000 | 1,000 | 6,540,000 | 1,074,000 | 5,747,000 | 0 | 6,107,000 | 0 | 5,704,000 | 0 | 5,675,000 | 0 | 4,899,000 | 0 | 4,245,000 | 0 | 3,866,000 | 600,000 | 3,563,000 | 165,000 | 3,521,000 | 52,000 | 3,555,000 | 264,000 | 3,437,000 | 172,000 | 3,475,000 | 228,000 | 6,810,000 | 833,000 | 3,402,000 | 7,594,000 | 4,712,000 | 1,751,000 | 3,817,000 | 3,152,000 | 4,568,000 | 2,288,000 | 6,463,000 | 8,638,000 | 17,331,000 | 5,806,000 | 10,777,000 | 2,833,000 | 1,130,000 | 1,000 | 3,543,000 | 1,535,000 | 3,784 | ||||||||||||||
repurchase of common stock | 0 | -26,004,000 | -25,905,000 | -25,501,000 | 0 | -50,018,000 | 0 | -7,711,000 | -17,298,000 | 0 | -4,334,000 | 0 | -20,665,000 | -58,699,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided (used in) financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, beginning of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash, end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of cash flow information: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the year for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest | 104,000 | 37,000 | 11,000 | 12,000 | 15,000 | 64,000 | 4,000 | 3,000 | 51,000 | 44,000 | 2,000 | 11,000 | 152,000 | 16,000 | 38,000 | 42,000 | 29,000 | 75,000 | 367,000 | 94,000 | 98,000 | 546,000 | 1,104,000 | 1,555,000 | 149,000 | 1,494,000 | ||||||||||||||||||||||||||||||||||||||||
income taxes | 10,577,000 | 30,993,000 | 6,327,000 | 6,150,000 | 4,333,000 | 2,635,000 | 16,969,000 | 25,818,000 | 1,085,000 | 4,775,000 | 7,458,000 | 3,973,000 | 3,725,000 | 2,259,000 | 3,279,000 | 4,804,000 | 2,586,000 | 10,443,000 | 4,183,000 | 5,129,000 | 5,145,000 | 2,162,000 | 2,481,000 | 2,536,000 | 1,282,000 | 3,184,000 | ||||||||||||||||||||||||||||||||||||||||
cash received during the year for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncash investing and financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of discontinued operation | 0 | 0 | 0 | 25,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of other entities | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other | 0 | 0 | 63,000 | 684,000 | 1,271,000 | 347,000 | 170,000 | -370,000 | -72,000 | 523,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of operating right of use assets | 4,046,000 | 3,996,000 | 4,104,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on business combination | 0 | 0 | 0 | -5,416,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment and other charges | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefits from stock-based compensation arrangements | -1,451,000 | 122,000 | 912,000 | 1,681,000 | 743,000 | 1,121,000 | 1,569,000 | 1,678,000 | 137,000 | 382,000 | 100,000 | 2,000 | 0 | 8,000 | 77 | |||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from discontinued operations | 2,000 | -3,973,000 | 383,000 | -18,000 | -1,283,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
coherent, inc. and subsidiariesconsolidated statements of cash flows | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from long-term borrowings | 0 | 0 | 0 | 740,685,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid to subsidiaries' minority shareholders | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
debt issuance costs | 0 | -475,000 | -68,000 | -25,824,000 | -2,672,000 | -393,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
use of previously owned equity shares in acquisition | 0 | 0 | 0 | 20,685,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash pension benefit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid to subsidiaries’ minority shareholders | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
impairment of assets held for sale | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in cash overdraft | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other non-cash incomes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other non-cash expenses | 456,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other assets | -975,000 | -2,561,000 | 3,031,000 | -1,047,000 | 1,472,000 | -1,252,000 | 1,240,000 | -658,000 | -775,000 | -647,000 | 51,000 | -2,118,000 | 569,000 | -1,473,000 | 1,604,000 | -666,000 | -1,363,000 | 856,000 | 1,151,000 | -497,000 | 2,911,000 | -2,284,000 | 3,323,000 | 6,722,000 | -1,153,000 | |||||||||||||||||||||||||||||||||||||||||
net change in capital lease obligations | -2,000 | -4,000 | -4,000 | -3,000 | -4,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash and cash equivalents | 35,000 | -3,287,000 | 3,163,000 | -2,118,000 | -475,000 | 1,764,000 | -13,696,000 | -2,807,000 | -5,732,000 | -1,078,000 | 758,000 | 2,333,000 | 4,035,000 | 3,101,000 | -208,000 | 2,584,000 | 2,413,000 | -4,792,000 | 2,434,000 | -6,183,000 | -14,928,000 | -4,410,000 | 428,000 | 12,761,000 | 1,128,000 | 3,482 | 1,397,000 | 2,151,000 | -313,000 | -277,000 | 2,283,000 | 54,000 | 2,198,000 | 2,332,000 | 2,279,000 | |||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | 214,940,000 | -17,769,000 | 14,833,000 | 11,736,000 | 27,469,000 | -11,943,000 | -14,339,000 | 38,203,000 | -58,351,000 | 9,317,000 | 1,876,000 | 27,931,000 | 29,133,000 | -12,293,000 | 5,608,000 | 20,235,000 | 601,000 | -32,620,000 | 4,868,000 | 10,753,000 | 17,590,000 | 6,398,000 | -4,973,000 | 11,502,000 | 4,759,000 | |||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of period | 0 | 0 | 130,607,000 | 0 | 0 | 91,217,000 | 0 | 0 | 110,444,000 | 0 | 0 | 67,761,000 | 0 | 0 | 167,061,000 | 0 | 0 | 245,380,000 | 0 | 0 | 199,950,000 | 0 | 0 | 213,826,000 | 0 | 0 | 315,927,000 | 445,231 | 97,507,000 | 87,659,000 | 0 | 0 | 76,541,000 | 0 | 0 | 131,018,000 | 77,409,000 | |||||||||||||||||||||||||||||
cash and cash equivalents, end of period | -17,769,000 | 14,833,000 | 142,343,000 | -11,943,000 | -14,339,000 | 129,420,000 | 9,317,000 | 1,876,000 | 138,375,000 | -12,293,000 | 5,608,000 | 87,996,000 | -3,484,000 | -81,598,000 | 167,662,000 | -436,000 | -27,398,000 | 227,515,000 | 18,185,000 | -7,594,000 | 199,760,000 | -620,000 | -2,284,000 | 185,235,000 | 24,347,000 | -151,011,000 | 320,795,000 | 434,826 | 108,260,000 | 105,249,000 | 6,398,000 | -4,973,000 | 88,043,000 | -8,036,000 | -19,337,000 | 112,002,000 | 82,168,000 | |||||||||||||||||||||||||||||
other non-cash income | 518,000 | -376,000 | 24,000 | 360,000 | -988,000 | -354,000 | 10,000 | -32,000 | -130,000 | 183,000 | -222,000 | 522,000 | -567,000 | 252,000 | -266,000 | 154,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividend paid | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of hypertronics intangibles | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefit from stock-based compensation arrangements | 1,451,000 | -122,000 | -912,000 | -1,681,000 | -743,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of capital lease obligations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital lease repayments | 0 | -5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividend paid on common stock | 0 | 0 | -24,040,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by/(used in) financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash translation adjustment related to finland dissolution | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in restricted cash | 0 | 0 | 2,521,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of property and equipment | -337,000 | 360,000 | 170,000 | 42,000 | 61,000 | -328,000 | 411,000 | 156,000 | 118,000 | 233,000 | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the period for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash received during the period for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unpaid property and equipment | 797,000 | 53,000 | 1,000,000 | -2,166,000 | 1,844,000 | 1,933,000 | -1,846,000 | 1,939,000 | 889,000 | -176,000 | 306,000 | 654,000 | -310,000 | -62,000 | 1,554,000 | -410,000 | 1,551,000 | 872,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
investment in sionyx | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other-net | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets acquired under capital leases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from employee stock options | 2,572,000 | 564,000 | 955,000 | -6,000 | 48,000 | -1,295,000 | 1,543,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | -3,484,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of short-term borrowing | -4,786,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash gain on finland dissolution | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term repayments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash overdrafts decrease | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash restructuring and other charges | 146,000 | 904,000 | 230,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of capital lease obligations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of a business | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of property and equipment | 58,000 | 283,000 | 155,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash restructuring and other | 209,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of business | 0 | 0 | 6,519,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other—net | -518,000 | 75,000 | 729,000 | 196 | 1,340,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash overdrafts increase | 831,000 | 216,000 | 786,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
retirement of restricted common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net retirement of restricted stock awards | 327,000 | 370,000 | 24,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchased in-process research and development | 690,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(gain) loss on disposal of property and equipment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of bond issue costs | 292 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
premiums paid for life insurance contracts | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt repayments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
collection of notes receivable from common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
portion of deferred business acquisition costs included in other current liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
unrealized loss on equity securities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of capital lease obligation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
excess tax benefits from stock-based payment arrangements | 172,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities, net of acquisitions: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes payable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in restricted cash and cash equivalents | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred business acquisition costs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
premiums paid on life insurance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other – net | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds received from issuance of convertible subordinated notes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt borrowings | 3,000 | 23,000 | 49,000 | 288,000 | 8,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term debt payments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
sales of shares under employee stock plans | 3,596,000 | 3,584,000 | 2,482,000 | 2,124,000 | 2,317,000 | 7,432,000 | 472,000 | 2,921,000 | 4,201,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
collection of notes receivable from stock sales | 35,000 | 0 | 348,000 | 718,000 | 186,000 | 66,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash restructuring, impairment and other charges | 300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in restricted cash and cash equivalents | 4,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other — net | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tax benefit from stock option exercises | 60,000 | 225,000 | 164,000 | 417,000 | 78,000 | 134,000 | 200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
portion of iolon purchase price not yet paid | 512,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from continuing operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from continuing operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile income from continuing operations to net cash from continuing operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interest in subsidiaries’ losses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity in loss of joint ventures | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of joint venture | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of lumenis investment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-down of lumenis investment | 0 | 0 | 0 | 10,212,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of short-term trading investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of short-term trading investments | 93,998,000 | 84,243,000 | 26,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock under productivity incentive plan | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dividends paid to minority stockholders | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from continuing operating activities | 16,442,000 | 11,137,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from continuing investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of note receivable from picometrix | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses and minority interest, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in restricted cash, cash equivalents and short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
premiums paid for life insurance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions from deferred compensation plan arrangements | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
investment in joint venture | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of joint venture | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from continuing investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from continuing financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from continuing financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from discontinued operating activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net issuances of restricted stock awards | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of lumenis common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangible assets amortization | 1,493,000 | 1,504,000 | 1,770,000 | 1,929,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in restricted cash, cash equivalents and short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from dispositions of property and equipment and assets held for sale | 1,069,000 | 700,000 | 534,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of businesses and minority interests, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid during the quarter for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash received during the quarter for: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income from continuing operations to net cash from continuing operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of short-term trading investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-down of notes receivable from picometrix | 0 | 0 | 3,723,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
in-process research and development | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities | 6,846,000 | -11,532,000 | 14,788,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from discontinued operations | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
portion of purchase price related to pli acquisition included in other current liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in restricted cash, cash equivalents and short-term investments | -8,000 | 624,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
consolidation of picometrix under fin 46r | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from continuing operations after accounting changes | 2,730,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile income from continuing operations after accounting changes to net cash from continuing operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cumulative effect of accounting changes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
intangibles amortization | 947,000 | 835,000 | 908,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
minority interest in subsidiaries’ earnings | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity in (income) loss of joint ventures | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of medical segment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of note receivable from picometrix | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equipment acquired under capital leases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of notes related to sale of common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayment of acquisition obligation through issuance of common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
activity resulting from sale of medical segment: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shares of lumenis common stock received | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
note receivable from lumenis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock-based compensation charge | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income tax expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile income from continuing operations to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restructuring and impairment charges | 339,000 | 405,000 | 16,438,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill impairment | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
restricted cash | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of available-for-sale investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales and maturities of available-for-sale investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of business, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other - net | 509,000 | 978,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile income from continuing operations after accounting changes to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other adjustments | 634,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash overdrafts |
We provide you with 20 years of cash flow statements for Coherent stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Coherent stock. Explore the full financial landscape of Coherent stock with our expertly curated income statements.
The information provided in this report about Coherent stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.